Abstract:Policy Points Health care systems around the world rely on a range of methods to ensure the affordability of prescription drugs, including negotiating prices soon after drug approval and relying on formal clinical assessments that compare newly approved therapies with existing alternatives. The negotiation framework established under the Inflation Reduction Act is far more limited than other frameworks explored in this study. Adding elements from these frameworks could lead to more effective price negotiation in the United States. Context In 2022, Congress passed the Inflation Reduction Act, which allowed Medicare, for the first time, to begin negotiating the prices for certain high‐cost brand‐name prescription drugs. Many other industrialized countries negotiate drug prices, and we sought to compare and contrast key features of the negotiation process across several health systems. We focused, in particular, on the criteria for selecting drugs for price negotiation, procedures for negotiation, factors that influence negotiated prices, and how prices are implemented. Methods We included four G7 countries in our analysis (Canada, France, Germany, and the United Kingdom [England]), two Benelux countries (Belgium and the Netherlands), and one Scandinavian country (Norway) with long‐established frameworks for drug price negotiation. We also analyzed the Veterans Affairs Health System in the United States. For each system, we gathered relevant legislation, government publications, and guidelines to understand negotiation frameworks, and we reached out to key drug price negotiators in each system to conduct semistructured interviews. All interviews were recorded, transcribed, and coded, and data were analyzed based on an internal assessment tool that we developed. Findings All eight systems negotiate the prices of brand‐name prescription drugs soon after approval and rely on formal clinical assessments that compare newly approved drugs with existing therapies. Systems in our study differed on characteristics such as whether the body performing clinical assessments is separate from the negotiating authority, how added health benefit is assessed, whether explicit willingness‐to‐pay thresholds are employed, and how specific approaches for priority disease areas are taken. Conclusions High‐income countries around the world adopt different approaches to conducting price negotiations on brand‐name drugs but coalesce around a set of practices that will largely be absent from the current Medicare negotiation framework. US policymakers might consider adding some of these characteristics in the future to improve negotiation outcomes.

Drug pricing and transparency in Europe and the United States: what is it and how does it work?

Pharmaceutical pricing in Europe: time to take the right direction

Value-based pricing of drugs with multiple indications or in combinations — lessons from Europe

Talkin' About a Resolution: Issues in the Push for Greater Transparency of Medicine Prices

A bibliometric analysis and typology of drug pricing policies across the globe

Price Transparency in United States' Health Care: A Narrative Policy Review of the Current State and Way Forward

Future European health care: cost containment, health care reform and scientific progress in drug research

Question-based drug development and the value of novel treatments

Common Pharmaceutical Price and Cost Controls in the United Kingdom, France, and Germany: Lessons for the United States

A Comparative Analysis of International Drug Price Negotiation Frameworks: An Interview Study of Key Stakeholders

Addressing the challenge of high-priced prescription drugs in the era of precision medicine: A systematic review of drug life cycles, therapeutic drug markets and regulatory frameworks

Prices of new medicines: International analysis and policy options

Pharmaceutical policies in European countries

New pricing models for generic medicines to ensure long-term sustainable competition in Europe

Medicare Drug Price Negotiation in the United States: Implications and Unanswered Questions

Towards ethical drug pricing: the European Orphan Genomic Therapies Fund

Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications

Learnings from cross-border biosimilar pricing policies in Europe

Importance of aligning the implementation of new payment models for innovative pharmaceuticals in European countries

Supplementary protection certificates and their impact on access to medicines in Europe: case studies of sofosbuvir, trastuzumab and imatinib

Employer Strategies for Health Care Price Transparency